Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in
treating patients with multiple myeloma that has come back (relapsed) or does not respond to
treatment (refractory). Panobinostat may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Chemotherapy drugs, such as carfilzomib and
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple
myeloma cells from patients' blood samples, the researchers will do laboratory tests to look
at how well each of the drugs, alone and in different combinations, kill multiple myeloma
cells. If the laboratory tests work well, they may be used in the future to help plan
treatment for future patients.